**Core Concept:**
The question is asking about a biologic agent used for the treatment of psoriasis or psoriatic arthritis, specifically whether it is an anti-TNF-a (tumor necrosis factor-alpha) agent or not. TNF-a is a pro-inflammatory cytokine involved in the pathogenesis of psoriasis and psoriatic arthritis, making anti-TNF-a therapy a potential treatment option.

**Why the Correct Answer is Right:**
The correct answer, D. Secukinumab, is a biologic agent specifically targeting interleukin-17 (IL-17) and not TNF-a. Interleukin-17 is also involved in the pathogenesis of psoriasis and psoriatic arthritis, but targeting it is different from targeting TNF-a. Secukinumab is a monoclonal antibody that inhibits IL-17A, which helps reduce inflammation and improve symptoms in these conditions.

**Why Each Wrong Option is Incorrect:**
A. Adalimumab (Humira) is an anti-TNF-a biologic agent and thus incorrect for the given question.
B. Etanercept (Enbrel) is also an anti-TNF-a biologic agent and should be rejected as well.
C. Infliximab (Remicade) is another anti-TNF-a biologic agent and is incorrect in this context.

**Why the Correct Answer is Right:**
Secukinumab is a monoclonal antibody that inhibits interleukin-17A, not TNF-a.

**Core Concept:**
TNF-a (tumor necrosis factor-alpha) is a pro-inflammatory cytokine involved in the pathogenesis of psoriasis and psoriatic arthritis. Targeting TNF-a with monoclonal antibodies can help reduce inflammation and improve symptoms in these conditions.

**Why Each Wrong Option is Incorrect:**
Option A (Adalimumab) and B (Etanercept) are monoclonal antibodies targeting TNF-a. Infliximab (option C) is a chimeric monoclonal antibody targeting TNF-a. All these options are incorrect because they target TNF-a, while the correct answer, Secukinumab, targets interleukin-17A.

**Clinical Pearl:**
Secukinumab is one of a class of biologic drugs called interleukin inhibitors, which target different inflammatory pathways than TNF-a inhibitors. Understanding the differences between these drug classes can be important for selecting the most appropriate treatment for individual patients with psoriasis or psoriatic arthritis.